Search
CD27 antigen
go.drugbank.com/bio_entities/BE0010071TargetHumansCostimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells (PubMed:28011863).
Synonyms: CD27L receptor, Tumor necrosis factor receptor superfamily member 7Tolterodine
go.drugbank.com/drugs/DB01036ApprovedInvestigationalTolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
Estradiol acetate
go.drugbank.com/drugs/DB13952ApprovedVet approved, estrone and estriol at the receptor level. … As a pro-drug of estradiol, estradiol acetate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located in
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigationalBrigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexPeginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalPeginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C.
Categories: Compounds used in a research, industrial, or household settingL-arginine
go.drugbank.com/drugs/DB17289ApprovedInvestigationalNutraceuticalMixtures: Quick Mix 2.5% Travasol Aa With Electrolytes With 25% Dextrose Injec, Clinimix 2.5% Travasol Aa Without Electrolytes In 10% Dextrose InjecDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalDaridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. … [L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].
Categories: Orexin Receptor AntagonistsDesogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigationalDesogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. … [A176339] It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity.
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedIt is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.
Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin Receptor AntagonistsChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class.
Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor Antagonists